Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EOLSNASDAQ:GNFTNYSE:NUVBNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$9.30+0.5%$10.27$8.67▼$17.82$599.62M1749,252 shs655,952 shsGNFTGENFIT$4.02-1.6%$4.08$2.55▼$6.42$201.99M1.1510,690 shs825 shsNUVBNuvation Bio$1.79+4.4%$2.15$1.54▼$3.97$609.07M1.372.73 million shs8.65 million shsREPLReplimune Group$9.49-0.2%$8.80$6.44▼$17.00$731.55M0.63889,776 shs849,942 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus0.00%-8.64%-6.63%-28.63%-12.59%GNFTGENFIT0.00%-0.35%-7.04%+10.63%-3.23%NUVBNuvation Bio0.00%-1.38%-17.36%-5.80%-38.45%REPLReplimune Group0.00%-4.04%+3.26%-12.29%+24.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEOLSEvolus3.9084 of 5 stars3.51.00.03.51.83.30.6GNFTGENFIT2.5106 of 5 stars3.55.00.00.02.70.00.0NUVBNuvation Bio3.4596 of 5 stars4.60.00.00.03.05.00.0REPLReplimune Group4.5255 of 5 stars3.63.00.04.53.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOLSEvolus 3.00Buy$23.75155.38% UpsideGNFTGENFIT 3.00Buy$13.00223.71% UpsideNUVBNuvation Bio 3.20Buy$7.17301.49% UpsideREPLReplimune Group 3.14Buy$20.83119.53% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, NUVB, EOLS, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.006/11/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.006/2/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.005/15/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.005/8/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/23/2025NUVBNuvation BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025NUVBNuvation BioCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$6.004/23/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$6.004/17/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOLSEvolus$266.27M2.25N/AN/A$0.09 per share103.33GNFTGENFIT$76.77M2.62$0.07 per share57.76$1.50 per share2.68NUVBNuvation Bio$7.87M77.17N/AN/A$1.37 per share1.30REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOLSEvolus-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)NUVBNuvation Bio-$567.94M-$2.35N/AN/AN/A-5,534.21%-44.14%-32.97%8/4/2025 (Estimated)REPLReplimune Group-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/6/2025 (Estimated)Latest GNFT, NUVB, EOLS, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/7/2025Q1 2025NUVBNuvation Bio-$0.16-$0.16N/A-$0.16$0.42 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEOLSEvolusN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOLSEvolus22.002.342.16GNFTGENFIT0.081.231.23NUVBNuvation BioN/A9.019.01REPLReplimune Group0.177.957.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOLSEvolus90.69%GNFTGENFIT2.24%NUVBNuvation Bio61.67%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipEOLSEvolus5.90%GNFTGENFIT4.20%NUVBNuvation Bio29.93%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOLSEvolus17064.48 million60.67 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableNUVBNuvation Bio60340.26 million238.42 millionOptionableREPLReplimune Group21077.09 million70.30 millionOptionableGNFT, NUVB, EOLS, and REPL HeadlinesRecent News About These CompaniesReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DEJune 14, 2025 | marketbeat.comReplimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 PlanJune 6, 2025 | quiverquant.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?June 4, 2025 | marketbeat.comWellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)June 3, 2025 | marketbeat.comPiper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock PriceJune 2, 2025 | marketbeat.comReplimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1, 2025 | globenewswire.comTwo Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)June 1, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from AnalystsJune 1, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?May 31, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's WhyMay 30, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLCMay 30, 2025 | marketbeat.comReplimune to Present at the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comHC Wainwright Estimates Replimune Group Q3 EarningsMay 27, 2025 | marketbeat.comLeerink Partnrs Estimates Replimune Group Q1 EarningsMay 27, 2025 | marketbeat.comReplimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA reviewMay 26, 2025 | investing.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LPMay 25, 2025 | marketbeat.comMillennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)May 25, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Here's WhyMay 24, 2025 | marketbeat.comTraders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)May 24, 2025 | marketbeat.comEarnings call transcript: Replimune Q1 2025 sees stock drop post-earningsMay 24, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNFT, NUVB, EOLS, and REPL Company DescriptionsEvolus NASDAQ:EOLS$9.30 +0.05 (+0.54%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$9.25 -0.05 (-0.54%) As of 06/18/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.GENFIT NASDAQ:GNFT$4.01 -0.07 (-1.59%) As of 06/18/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Nuvation Bio NYSE:NUVB$1.78 +0.08 (+4.39%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$1.84 +0.05 (+2.80%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Replimune Group NASDAQ:REPL$9.49 -0.02 (-0.21%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$9.99 +0.50 (+5.32%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
